Skip to main content

Advertisement

Fig. 5 | BMC Cancer

Fig. 5

From: PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes

Fig. 5

DRFS estimates in Luminal-A premenopausal patients treated with hormonal therapy alone (left) and chemotherapy plus hormonal therapy (right). In this cohort, a distant relapse occurred in 0% (0/12) PLCγ1-pY783Low and 66% (2/3) PLCγ1-pY783High of patients treated with hormonal therapy (n = 15), and in 0% (0/23) PLCγ1-pY783Low and 40% (4/10) PLCγ1-pY783High of patients treated with chemotherapy plus hormonal therapy (n = 33). The solid green line and dashed blue line represent high and low expression of PLCγ1-pY783, respectively

Back to article page